Syndax Pharmaceuticals IncSNDX
Price$18.22

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $252.3M+965.2% YoYTTM through 30 Jun 2026
Net Income -$220.8MTTM through 30 Jun 2026
Free Cash Flow -$220.8MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-77.1%
Operating Margin-52.7%
Net Margin-87.5%

Returns

-31.4%ROA

Balance Sheet Health

Debt / Equity23.18x
Current Ratio6.77x
Net Debt$13.5M
Cash & Equivalents$336.5M

Quality Metrics

Altman Z-Score-1.34
Piotroski F-Score4 / 9
FCF Margin-87.5%
Rule of 40-62.1
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $172.4M
Diluted EPS-$2.51TTM
'19'20'21'22'23'24'25
FY2025: $-3.29

Dividend

No dividend

Capital Allocation

Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.